Mar 26, 2024 | Commentary
Politicians—Democrats and Republicans alike—regularly complain about high drug prices and the need for policy changes to make prescription medicines more affordable for patients (read: voters).
Jan 8, 2024 | Commentary
Provider networks are a well-known tool health insurance companies use to keep down the cost of care.
Dec 7, 2023 | Commentary
Yesterday, the Initiative for Medicines, Access, and Knowledge I-MAK took an important step by proposing six policy solutions to address patent thickets that block generic and biosimilar drug competition.
Nov 2, 2023 | Commentary
Pharmacy benefit managers (PBMs) are a popular Congressional target of late.
Sep 26, 2023 | Commentary
As Congress stumbles toward a government shutdown, health policy legislation continues to simmer in the background.
Jun 26, 2023 | Commentary
In January, the 21-year monopoly for AbbVie’s blockbuster drug Humira (adalimumab) came to an end with the launch of Amjevita, Amgen’s biosimilar adalimumab.